COVID-19 vaccines’ effectiveness and safety exaggerated
in clinical trials & observational studies, academics find
By RAPHAEL LATASTER, PHD
An unofficial series of 4 crucially important medical journal articles, 2 by me, appearing in major academic publisher Wiley’s Journal of Evaluation in Clinical Practice reveals that claims made about COVID-19 vaccines’ effectiveness and safety were exaggerated in the clinical trials and observational studies, which significantly impacts risk-benefit analyses. Also discussed are the concerning topics of myocarditis, with evidence indicating that this one adverse effect alone means that the risks outweigh the benefits in the young and healthy; and perceived negative effectiveness, which indicates that the vaccines increase the chance of COVID-19 infection/hospitalisation/death, to say nothing about other adverse effects.
Whilst already planning for a holiday overseas on the advice of my treating team, I fortuitously was invited to share my research and discuss my ongoing persecution alongside brilliant and courageous doctors, scientists, academics, lawyers, and activists, such as Dr Robert Malone, who declared this research to be “excellent”, and “some of the best work, academically, in reevaluating the data”, culminating in an invitation to testify for US Senator Ron Johnson. So for those who are here because of the associated videos, and anyone else interested in this topic, please enjoy this much more detailed summary.
Introduction
In early 2023 pharmacy researcher Peter Doshi, one of the editors of the prestigious British Medical Journal, and contributor to the excellent Fraiman et al. analysis on the mRNA vaccine clinical trials (source, OTN entry), published an important study (Article 1, source, OTN entry) with statistician Kaiser Fung and biostatistician Mark Jones on biases in observational studies of COVID-19 vaccines. The highlight was the discussion on the case-counting window bias, which affects effectiveness estimates. Building on this effort, misinformation researcher and former pharmacist Raphael Lataster (that’s me) published a paper (Article 2, source, OTN entry) noting that, amongst other things, such counting window issues could also affect estimates of safety in observational studies.
Doshi and Fung then returned serve with a discussion (Article 3, source, OTN entry) on how case-counting window issues also affected estimates of effectiveness in the Pfizer and Moderna clinical trials. Ending the unofficial series, Lataster produced an article (Article 4, source, OTN entry) explaining that the clinical trials also were plagued with adverse effect counting window issues which likely led to exaggerated safety estimates. Together, these 4 articles make clear that claims made about COVID-19 vaccines’ effectiveness and safety were exaggerated in the clinical trials and observational studies, whilst also finding time to discuss myocarditis and perceived negative effectiveness, meaning that new risk-benefit analyses are very much needed.
For much more on this story, please continue reading at:
No comments:
Post a Comment